Clinical Trials
4 trialsNCT03982121 2020-02-17
ISILI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Withdrawn
NCT02320305 2020-01-14
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT02180698 2019-11-06
TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT02035657 2018-06-13
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Completed